Arcturus Therapeutics (NASDAQ: ARCT) net income
Arcturus Therapeutics reported a net loss of $65.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $80.9m. Earnings per share were −$2.40.
Arcturus Therapeutics's best year of the last 8 was fiscal 2022. It reported a loss in 7 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$65.8m | — | −80.2% | −$2.40 |
| 2024 | −$80.9m | — | −53.1% | −$3.00 |
| 2023 | −$29.7m | −417.9% | −17.8% | −$1.12 |
| 2022 | $9.3m | — | 4.5% | $0.35 |
| 2021 | −$203.7m | — | −1,648.0% | −$7.74 |
| 2020 | −$72.1m | — | −756.3% | — |
| 2019 | −$26.0m | — | −125.0% | — |
| 2018 | −$21.8m | — | −138.3% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arcturus Therapeutics net income compared with its sector
By net income for its latest fiscal year, Arcturus Therapeutics ranks 285th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Arcturus Therapeutics, −80.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 283rd | Omniab | −$64.8m | −347.0% |
| 284th | Aclaris Therapeutics | −$64.9m | −829.6% |
| 285th | Arcturus Therapeutics | −$65.8m | −80.2% |
| 286th | Tarsus Pharmaceuticals | −$66.4m | −14.7% |
| 287th | Compass Therapeutics | −$66.5m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Arcturus Therapeutics
- How much did Arcturus Therapeutics earn in fiscal 2025?
- Arcturus Therapeutics reported a net loss of $65.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $80.9m.
- What are the earnings per share of Arcturus Therapeutics?
- They were −$2.40 in fiscal 2025, compared with −$3.00 in fiscal 2024.
- What was the most profitable year for Arcturus Therapeutics?
- Of its last 8 fiscal years, fiscal 2022, with $9.3m.
- Where does Arcturus Therapeutics rank in its sector by net income?
- It ranks 285th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Arcturus Therapeutics come from?
- From the annual report (Form 10-K) that Arcturus Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arcturus Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Arcturus Therapeutics: the Arcturus Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.